A panel of medical experts listened to compelling and often emotional testimony Tuesday from multiple sclerosis patients who say the drug Tysabri succeeded in bettering their lives after other medications had failed. The testimony was presented on the first day of a two-day meeting before a Food and Drug Administration advisory panel convened to decide whether Tysabri is safe enough to again be sold. One of the people who appeared before the committee was a woman from Oregon who says she tried three treatments without seeing improvements before Tysabri. However, after one infusion of Tysabri, she says her muscle spasms stopped. Now the woman, who says she has no financial interest in either of the drug's marketers, Biogen Idec ( BIIB) and Elan ( ELN), wants to decide for herself if she should continue taking it, an option that she currently doesn't have. Those comments were echoed by other of the drug's supporters, many of whom said they simply want to have the choice of using Tysabri. In what some patients at the hearing called an overreaction, Tysabri was pulled from the market in February 2005 after being linked to a potentially fatal brain illness. Much more will be known about the drug's fate after the advisory committee meeting wraps up Wednesday. The group will make recommendations as to whether the FDA should clear the drug and under what circumstances. Many analysts expect that Tysabri will ultimately return to the market, but that certain restrictions might be placed on its use. Tysabri was withdrawn after being connected to a disease called progressive multifocal leukoencephalopathy. Two PML cases appeared in MS patients who took Tysabri along with another Biogen MS treatment, Avonex. A patient who received Tysabri during a Crohn's disease trial was later found to have PML. In two of the cases, the patients died.